Syros Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
A Syros Pharmaceuticals director, Nancy A. Simonian, sold 37,070 shares of common stock at a weighted average price of $0.2702 on December 2, 2024.
OTC.Pink
A Syros Pharmaceuticals director, Nancy A. Simonian, sold 134,713 shares of common stock at a weighted average price of $0.2653.
OTC.Pink
Kristin Stephens, Chief Development Officer of Syros Pharmaceuticals, sold 36,133 shares of common stock at $0.22 per share on November 18, 2024.
OTC.Pink
Syros Pharmaceuticals' Chief Medical Officer, David Roth, sold 12,099 shares of common stock at an average price of $0.1969 per share on November 18, 2024.
OTC.Pink
A Syros Pharmaceuticals executive, Gerald E Quirk, sold 46,657 shares of common stock at a weighted average price of $0.2212.
OTC.Pink
Syros Pharmaceuticals' CEO, Chee Conley, sold 134,797 shares of common stock at a weighted average price of $0.1998 on November 18, 2024.
OTC.Pink
Syros Pharmaceuticals' Chief Financial Officer, Jason Haas, sold 137,803 shares of common stock at a weighted average price of $0.2103 per share.
OTC.Pink
Director Nancy A. Simonian reported the vesting of restricted stock units and subsequent acquisition of Syros Pharmaceuticals common stock on October 31, 2024.
OTC.Pink
Chief Medical Officer David Roth reports stock transactions related to restricted stock units of Syros Pharmaceuticals.
OTC.Pink
Chief Financial Officer of Syros Pharmaceuticals, Jason Haas, reports the vesting of restricted stock units and subsequent tax withholding.
OTC.Pink
Syros Pharmaceuticals' CEO, Chee Conley, reports the vesting of restricted stock units and subsequent stock transactions.
OTC.Pink
Kristin Stephens, Chief Development Officer at Syros Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
OTC.Pink
Gerald E. Quirk, Chief Legal & Compliance Officer of Syros Pharmaceuticals, exercised stock options and sold shares to cover tax obligations on September 30, 2024.
OTC.Pink
Director Akkaraju Srinivas of Syros Pharmaceuticals reports the vesting of restricted stock units and subsequent disposal of shares.
OTC.Pink
Director Richard A. Young of Syros Pharmaceuticals reports the vesting of restricted stock units and subsequent disposal of shares.
OTC.Pink
Syros Pharmaceuticals' CEO, Conley Chee, recently acquired 100,000 shares of company stock in two separate transactions, signaling confidence in the company's future.
OTC.Pink
Syros Pharmaceuticals' Chief Financial Officer, Jason Haas, recently acquired a significant number of company shares through a series of open market purchases.
OTC.Pink
Director Richard A. Young sold 34,837 shares of Syros Pharmaceuticals (SYRS) at $5.12 per share on June 28, 2024, according to a Form 4 filing.
OTC.Pink
Form 4: Syros Pharmaceuticals Director Nancy A. Simonian Reports Acquisition of Shares and Stock Options
Director Nancy A. Simonian reports acquiring 4,000 shares of common stock and stock options for 6,000 shares in Syros Pharmaceuticals.
OTC.Pink
Director Richard A. Young of Syros Pharmaceuticals acquired 4,000 shares of common stock and options to purchase 6,000 shares on June 5, 2024.
OTC.Pink
Director Timothy Tyson acquired 4,000 shares of common stock and options to purchase 6,000 shares of Syros Pharmaceuticals on June 5, 2024.
OTC.Pink
Director Deborah Dunsire reports the acquisition of stock options and restricted stock units (RSUs) in Syros Pharmaceuticals.
OTC.Pink
Director Andrew M. Oh acquired 4,000 shares of common stock and options to purchase 6,000 shares of Syros Pharmaceuticals on June 5, 2024.
OTC.Pink
Form 4: Syros Pharmaceuticals Director Sue Gail Eckhardt Reports Stock Option Grant and Stock Acquisition
Director Sue Gail Eckhardt reports acquisition of 4,000 shares of common stock and grant of stock options for 6,000 shares of Syros Pharmaceuticals.
OTC.Pink
Director Akkaraju Srinivas of Syros Pharmaceuticals reports the acquisition of stock options and restricted stock units (RSUs) on June 5, 2024.
OTC.Pink
Director Marsha Fanucci acquired 4,000 shares of common stock and stock options for 6,000 shares of Syros Pharmaceuticals on June 5, 2024.
OTC.Pink
Form 4: Syros Pharmaceuticals Director Peter Wirth Reports Stock Option Grant and Share Transactions
Director Peter Wirth reported the acquisition of stock options and shares of Syros Pharmaceuticals on June 5, 2024.
OTC.Pink
Director Deborah Dunsire reports acquisition of 4,000 shares of Syros Pharmaceuticals common stock upon vesting of restricted stock units.
OTC.Pink
Director Akkaraju Srinivas reports the vesting of restricted stock units and subsequent sale of shares of Syros Pharmaceuticals common stock on June 1, 2024.
OTC.Pink
David Roth, Chief Medical Officer of Syros Pharmaceuticals, sold 10,451 shares of common stock on April 3, 2024, at a price of $4.95 per share.